CAR-T细胞药物是抗击癌症的一种革命性疗法,近年来发展迅速,已经造福了白血病、淋巴瘤、骨髓瘤等许多血液癌症患者,但在实体瘤中,还未有药物真正获批上市。 6月25日,港股企业科济药业(02171.HK)宣布,舒瑞基奥仑赛注射液(一种靶向Claudin18.2的自体CAR-T细胞产品)的新药上市申请已正式提交至中国药品审评中心,用于治疗Claudin18.2表达阳性、至少二线治疗失败的晚期胃/食管...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.